The biotechnology company Orikine Bio, recently established at the Barcelona Science Park, has received an investment of €2.7 million from the SICC Innvierte of CDTI Innovación together with the fund managers Asabys Partners (Sabadell Asabys Health Innovation Investments II, FCR and Sabadell Asabys Health Innovation Investments 2B, SCR SA) and AdBio Partners (AFB Seed Fund II). With this capital injection, the company will continue to drive the development of a new generation of therapies for autoimmune, inflammatory and oncological diseases.
CDTI Innovación, through Innvierte, has closed an investment deal in this biotechnology company together with Sabadell Asabys Health Innovation Investments II, FCR; Sabadell Asabys Health Innovation Investments 2B, SCR SA; and AFB Seed Fund II, for a total amount of €2.7 million. With this participation, CDTI Innovación helps to improve people’s health and well-being by promoting the development of products that accelerate patient recovery.
Orikine Bio has a team made up of experts in biotechnology, immunology, protein engineering, and business development. Their main objective is to develop therapies capable of “reprogramming” the immune system, in a similar way to how software engineers rewrite faulty code to repair computer systems.
Their proprietary Foldikine™ platform designs bispecific cytokines—molecules that send precise, targeted instructions to immune cells in a specific, effective, and safe manner. By reprogramming these cells, they restore proper immune function and offer innovative solutions for conditions such as autoimmune diseases and chronic inflammation.
With this new investment and the technological boost provided by the Foldikine™ platform, Orikine Bio strengthens its growth potential and consolidates its commitment to developing innovative therapies that improve people’s quality of life. The operation represents a step forward in translating scientific knowledge into high‑impact solutions for the healthcare system.
Access to the news: CDTI website [+]
Imagen: Orikine's Bio team at the Barcelona Science Park. Photo / Orikine Bio
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
El Hospital Universitario de Bellvitge y el Instituto de Investigació...
